Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 3, 2005, Pages 217-222

  Keene, Kimberly S ^a   Harman, Eloise M ^a   Knauf, Daniel G ^a   McCarley, Dean ^a   Zlotecki, Robert A ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Cisplatin; Clinical trials phase II; Lung neoplasms; Outcome studies; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; STEROID;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RADIATION DOSE FRACTIONATION; STEROID THERAPY; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; ESOPHAGITIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE TABLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RADIATION INJURIES; RADIATION PNEUMONITIS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, HIGH-ENERGY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 20444414494     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000145986.78542.44     Document Type: Article

References (21)

1. Cox JD, Azamia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses 60.0 Gy to 79.2 Gy; possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma; report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 1990;8:1543-1555.
2. Schaake-Koning C, Maat B, Van Houtte P, et al. Radiotherapy combined with low-dose cis-diammine dichloroplatinum (II) (CDDP) in inoperable nonmetastatic non-small cell lung cancer (NSCLS): a randomized three arm phase II study of the EORTC Lung Cancer and Radiotherapy Cooperative Groups. Int J Radiat Oncol Biol Phys. 1990;19:967-972.
3. Cox JD, Pajak TF, Herskovic A, et al. Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung (NSCLC): 1. C Results of the RTOG protocol 81-08. Am J Clin Oncol. 1991;14:280-284.
4. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87: 198-205.
5. Uitterhoeve AL, Belderbos JS, Koolen MG, et al. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer. Eur J Cancer. 2000;36:592-600.
6. Komaki R, Scott C, Lee JS, et al. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06. Am J Clin Oncol. 1997;20:435-440.
7. Nathu RM, Mendenhall WM, Parsons JT, et al. Induction chemotherapy and radiation therapy for T4 oropharyngeal carcinoma. Radiat Oncol Investig. 1999;7:98-105.
8. Choy H, Devore RF III, Hande KR, et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys. 2000;47:931-937.
9. Socinski MA, Rosenman JG, Schell MJ, et al. Induction carboplatin/ paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I trial. Cancer. 2000; 89:534-542.
10. Choy H, Akerley W, Safran H, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 1998;16:3316-3322.
11. Kubota K, Tamura T, Fukuoka M, et al. Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902. Ann Oncol. 2000;11:445-450.
12. Vora SA, Daly BD, Blaszkowsky L, et al. High dose radiation therapy and chemotherapy as induction treatment for stage III nonsmall cell lung carcinoma. Cancer. 2000;89:1946-1952.
13. Lau D, Leigh B, Gandara D, et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/ paclitaxel consolidation for stage III non-small-cell lung cancer: A California Cancer Consortium phase II trial. J Clin Oncol. 2001;19:442-447.
14. Klasterksky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990;8:1556-1562.
15. Kucuk O, Shevrin DH, Pandya KJ, et al. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000;23:371-375.
16. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (ROTG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys. 2000;48:1475-1482.
17. Donaldson N, Dillman RO, Wallace J, et al. Sequential re-analysis of a phase-III clinical trial in non-small cell lung cancer. Eur Respir J. 2000;15:821-827.
18. Lochrin C, Goss G, Stewart DJ, et al. Concurrent chemotherapy with hyperfractionated accelerated thoracic irradiation in stage III non-small cell lung cancer. Lung Cancer. 1999;23:19-30.
19. Russell AH, Pajak TE, Selim HM, et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1991;21:637-643.
20. Stuschke M, Eberhardt W, Pottgen C, et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol. 1999;17:2700-2709.
21. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vendestine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692-2699.